v3.26.1
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Mar. 31, 2026
Dec. 31, 2025
Current assets    
Cash and cash equivalents $ 7,566 $ 374
Accounts receivable 3 3
Research and development tax credit receivable 536 549
Prepaid expenses and other current assets 696 575
Total current assets 8,801 1,501
Property, plant and equipment, net 141 180
Right-of-use assets, net 535 607
Total assets 9,477 2,288
Current liabilities    
Accounts payable and accrued expenses 3,357 4,603
Lease liabilities, current 277 271
Notes payable, net 101 928
Deferred revenue 106 108
Total current liabilities 3,841 5,910
Lease liabilities, non-current 230 312
Total liabilities 4,071 6,222
Contingencies (Note 9)
Stockholders' equity / (deficit):    
Preferred stock, par value $0.0001 per share, 10,000,000 shares authorized, 21,411.5 and 0 shares issued and outstanding, at March 31, 2026 and December 31, 2025, respectively
Common stock, par value $0.0001 per share, 300,000,000 shares authorized, 21,202,911 and 6,839,689 shares issued and outstanding, at March 31, 2026 and December 31, 2025, respectively 2 1
Additional paid-in capital 152,570 124,772
Accumulated other comprehensive loss (2,668) (3,578)
Accumulated deficit (144,498) (125,129)
Total stockholders' equity / (deficit) 5,406 (3,934)
Total liabilities and stockholders' equity / (deficit) $ 9,477 $ 2,288

Source

HTML PDF
ZIP